Acute Leukemias

Acute Leukemias

A collection of features and news articles published in ASH Clinical News related to acute leukemias.

Aveo and Biodesix Stop Trials of Ficlatuzumab for Acute Myeloid Leukemia

Aveo and Biodesix have decided to stop all trials of their hepatocyte growth factor inhibitory antibody ficlatuzumab for acute myeloid leukemia (AML), citing the...

Can Dasatinib Overcome the Negative Effects of KIT Mutations in Core Binding Factor AML?

A chemotherapy regimen of cytarabine and daunorubicin plus dasatinib was well tolerated in patients with previously untreated core binding factor acute myeloid leukemia (CBF-AML)...
WIB_icon

Germline RUNX1 Mutations in RUNX1-Mutated AML More Frequent Than Previously Thought

A small study in Canada shows that the frequency of germline RUNX1 mutations in patients with RUNX1-mutated acute myeloid leukemia (AML) is higher than...

HCT Recipients Acquire Rare, Potentially Harmful Clonal Mutations Harbored by Younger Donors

Some patients with acute myeloid leukemia (AML) who received a hematopoietic cell transplantation (HCT) from young donors acquired rare, yet potentially harmful, clonal mutations...
WIB_icon

Blinatumomab Leads to High Remission Rate in Infants With Persistent MRD-Positive ALL

Treatment with the bispecific CD19/CD3 antibody blinatumomab induced molecular remissions in most infants with persistent measurable residual disease (MRD)–positive acute lymphocytic leukemia (ALL), according...

Gilead Acquires Magrolimab Manufacturer Forty Seven, Inc. for $4.9 Billion

In its largest acquisition since purchasing Kite Pharma in 2017, Gilead announced that it has acquired cancer biotech Forty Seven, Inc. for $4.9 billion. Forty...
On location

Early-Phase Study Shows Promising Response Rates With Venetoclax Plus Navitoclax in ALL

Nearly half of patients with relapsed/refractory acute lymphocytic leukemia (ALL) had a complete response (CR) after treatment with a combination of venetoclax and navitoclax,...

Study Finds No Benefit With Post-Induction Treatment Intensification in Children With ALL

According to results from the Children’s Oncology Group AALL0331 trial, pediatric patients with standard-risk B-cell acute lymphocytic leukemia (ALL) had a high rate of...

Early Peripheral Blast Cell Clearance Predicts Response to Induction Chemotherapy in Acute Myeloid Leukemia

Early peripheral blast cell clearance (PBC) assessed by leukocyte differential is well established as a predictor of leukemia induction outcome, but measuring PBC by...

HHS Allows Novartis to Pay Travel Expenses for Tisagenlecleucel Patients

The U.S. Department of Health and Human Services (HHS) will allow Novartis to cover travel, lodging, and meal expenses for Medicaid and Medicare beneficiaries...
Advertisement

Current Issue

April 2020, Volume 6, Issue 5

This issue examines current immunization guidelines for patients with hematologic disorders, considers medical education amid the coronavirus pandemic, and more.